Andrew Hirsch
Known title: President & CEOCIK: 0001586707
Andrew Hirsch's purchase track record
Andrew Hirsch has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/12/2022 | CCCC | $84K | +10.6% | -13.5% | -18.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CCCC | ▲ Buy | Option Exercise | 20,400 | $0 | 2/15/2026 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 9,057 | $17K | 2/15/2026 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 81,725 | $0 | 2/14/2026 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 39,154 | $74K | 2/14/2026 | View on chart |
| CCCC | ▲ Buy | Grant | 700,000 | $0 | 2/13/2026 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 9,370 | $30K | 2/15/2025 | View on chart |
| CCCC | ▲ Buy | Grant | 223,500 | $0 | 2/14/2025 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 12,847 | $41K | 2/14/2025 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 12,500 | — | 11/7/2024 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 5,550 | $34K | 11/7/2024 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 3,329 | $21K | 9/16/2024 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 7,500 | — | 9/16/2024 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 6,560 | $52K | 2/15/2024 | View on chart |
| CCCC | ▲ Buy | Grant | 103,400 | $0 | 2/14/2024 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 7,500 | — | 8/30/2023 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 2,205 | $6K | 8/30/2023 | View on chart |
| CCCC | ▲ Buy | Grant | 81,600 | $0 | 2/15/2023 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 4,319 | $34K | 1/30/2023 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 12,500 | — | 1/30/2023 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 12,500 | — | 5/25/2022 | View on chart |
| CCCC | ▲ Buy | Open Market | 10,000 | $84K | 4/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials
C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials. C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.